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Abstract
Background:  The aim of this study was first, to investigate whether women starting oral
contraceptive (OC) use at a young age and before first birth have an increased risk for breast
cancer and second, to report difficulties encountered in studying long-term health impacts of
medical technologies.
Methods: Breast cancers occurring up until 1997 among 37153 Helsinki students born between
1946 and 1960 were identified by record linkage from the Finnish Cancer Registry; for each cancer
case, five age-matched random controls were picked from the same student population. Those who
had used the Helsinki Student Health Service (HSHS) at least three times (150 cases and 316
controls) form the final study subjects. Data on OC use and background characteristics were
collected from patient records, and data on live births were derived from the population register.
Odds ratios (OR) were adjusted for number of births, smoking and sports activity.
Results: Compared to the few non-users, OC users had a higher risk of breast cancer: the
adjusted OR was 2.1 (95% confidence interval 1.1–4.2). Among OC users, no statistically significant
differences in risk of breast cancer were found in regard to starting age or first birth, but small
numbers made confidence intervals wide. Even though we had chosen students to be our study
group, the population turned out to be unsuitable to answer our research question: most women
had started their OC use old (at the age of 20 or later) and there were very few unexposed (almost
all had used OC and before their first birth).
Conclusions: Because adoption of the modern pattern of OC use was not common among
students, it is unlikely that the impact of early and extended OC use can be studied before 2010,
when women born in the 1960s are 40 to 50 years old.
Background
Epidemiological studies give varying results in regard to
whether oral contraceptive (OC) use is a risk factor for
breast cancer. A thorough meta-analysis based on epide-
miological studies up to the mid-1990s concluded that
women who have used combined OCs in the past 10 years
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are at a slightly increased risk of having breast cancer, al-
though the excess cancers diagnosed tended to be local-
ised [1,2]. Some of the later studies concluded that OC use
is a risk factor for breast cancer [3–10], or is for some sub-
groups [11,12], while other studies have not [13–16].
Young women having used the pill for a long time before
their first pregnancy have been identified as a potential
risk group [6,14,17,18], but currently there are not
enough studies to prove or disprove the increased risk of
breast cancer [19].
OCs were introduced into clinical use in the early 1960s.
Their use spread rapidly, but in the beginning they were
used mainly by women older than 20 years, after the first
birth, and intermittently; that is, for short periods of time
[20]. Over time the OC use patterns have radically
changed in many countries: start in the teen-years, use for
a long time before the first pregnancy, and continuous use
have increased and the type of pill has changed [6,20–23].
In Finland, 7% of 16-year-old girls and 22% of 18-year-
old girls used OCs in 1981; by the year 1989 figures had
increased to 17% and 38% [24] and have remained high
[25]. In 1997 one third of girls had experienced their first
sexual intercourse by the age of 16 years [26] and in 1998
the mean age at having the first child was 28 years [27]
The original purpose of this study was to see whether
women who started OC use young and before their first
birth have an increased risk for breast cancer before men-
opause. The study was done among Finnish students who
used the Helsinki Student Health Service (HSHS), and
cancers were identified by record linkage to the Finnish
Cancer Registry. However, as shown below, we ended up
with a low study power, and a second purpose of this ar-
ticle is to report the reasons to it to help others designing
studies on OC use and breast cancer.
Subjects and methods
This is a case control study among defined student popu-
lations. The first study base consisted of all Finnish female
Helsinki University students from 1965 onwards who
were born in the 1946–1960 period (n = 28109) and were
customers of the HSHS. The second study base was female
students of other higher educational institutions in the
Helsinki area who used the HSHS in 1980 or later (n =
9044). Most Helsinki students used the HSHS because be-
longing to the programme was compulsory and everyone
had to pay the health service fee, and municipal public
health care, with the exception of emergencies, was re-
stricted to municipality residents. Students could use pri-
vate services. The HSHS had very low fees for visits, and
once students entered the system they usually used its
services. In 1971, the first gynaecologists were employed
by the HSHS.
To identify those who later got breast cancer, the data on
the women in the study bases were linked to data in the
Finnish Cancer Registry for 1967 to 1997 using unique
personal identification (ID) numbers; since 1967 these
ID-numbers have been given to everyone who has lived in
Finland. The Finnish Cancer Registry has operated since
1953 and is based on compulsory notifications by physi-
cians who diagnose a malignant disease; the data in this
register were completed with information from hospitals,
laboratory records and death certificates. The notification
rate and accuracy of the registry are high [28]. Through the
linkage, 396 cases were found. For each cancer case, five
random controls (total 1980), matched for year of birth,
were chosen from the same study bases.
A requirement of at least three visits to HSHS, other than
the initial health check-up or a visit to a dentist or an oph-
thalmologist, was set to exclude women who had sought
their health care and OCs from other sources. Number of
visits was determined by manually searching the HSHS ar-
chives; 153 cases and 314 controls had at least three visits.
For 14 cases no controls remained. For them, one new
control, born in the same year, was randomly picked from
the 388 leftover controls (i.e. controls whose matched
case had not used services at least three times). The dates
of live births and women's vital status were obtained by
record linkage to the population register. Cases whose first
HSHS visit was after the breast cancer diagnosis (n = 3)
and controls who had died before or whose first visit was
after the time of the diagnosis of breast cancer in the case
(n = 12) were excluded. Altogether 150 cases and 316 con-
trols remained for analysis. Two cases had a carcinoma in
situ, others a malignant tumour; 80% were ductal carcino-
mas. By the end of 1997, 17 women in the case group
(11%) had died of breast cancer.
Data on exposure to OCs, reproductive history and back-
ground characteristics were collected from the HSHS pa-
tient records. A trained research nurse blind to the case-
control status abstracted the data. To identify OC use, a
list of all OCs on the Finnish market in the 1962–1985 pe-
riod was made with the help of old drug catalogues. The
HSHS kept continuous patient records in which all pre-
scriptions were marked. Information on OC use while an
HSHS customer was searched for from physicians' notes
and referral notes to the laboratory for PAP smears (at that
time, PAP smears were recommended to be regularly done
for OC users). In 1971 the HSHS introduced health status
questionnaires to be filled in at the first visit, including a
standard question on current and past OC use. Overall,
29% of women (25% of cases and 30% of controls) had a
note indicating OC use before entering HSHS. To describe
the women, the duration of OC use was calculated by
summing up the months from OC prescriptions, and theBMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/9
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estimates given in the records on prior use and on OCs
prescribed outside the HSHS.
Using all available data in HSHS documents, the year of
start of OC use was calculated. Exposure data were collect-
ed for all years up to the until one year prior to the breast-
cancer diagnosis of the case. For each woman the follow-
ing exposure data were constructed: OC use, age starting
OC use, and OC use before first live birth. Use of OCs was
classified into three classes: no (no, likely not), yes (yes,
likely yes), and not recorded. Women with any document-
ed use were included in the 'yes' class; the shortest dura-
tion was one month. The group 'not recorded' was a
mixed bag of women for whom there was some indication
of OC use, but no details of use ware available. It included
women who had a private gynaecologist or had received
an OC prescription, but who in later visits indicated no
OC use.
For one analysis, OC users were classified into the follow-
ing group: 1) started before the age of 23 years and before
first pregnancy, 2) other users (started older or after first
pregnancy or information on these characteristics was
lacking), 3) others. The cut-off point of 23 years was cho-
sen to get a reasonable number of women in each group.
Odds ratios (OR) and 95 % confidence intervals (CI) were
estimated using conditional logistic regression [29] with
GLIM 4 software [30]. The following data on potential
confounders were available in the patient records: study
discipline, weight and height, menarche age, menstrua-
tion cycle (average length and duration of bleeding),
smoking, alcohol use, participation in sports (either com-
petitive or other) at the first visit, and pregnancies at any
time while using the HSHS. Data on live births were ob-
tained from the population register. The odds ratios were
adjusted for smoking (never, ever, unknown), sports (no
sports, sports, unknown), and for parity and age at deliv-
ery.
Results
Breast cancer
The cases and controls were similar in terms of most stud-
ied background characteristics, but there were more con-
trols who were active in sports (Table 1). The proportions
of women having had births were relatively similar
among cases (73 percent) and controls (67 percent) and
the cases and controls had their first child about at the
same age (Table 1). In addition to the variables shown in
Table 1, we compared the cases and controls in terms of
how soon they entered the HSHS after starting their stud-
ies (for 60 % of cases and 64 % of controls the difference
between the first visit and starting year was less than 2
years), last visit to the HSHS (56% and 53% before 1980),
study institute (University of Helsinki for 90% and 93%),
distribution of weight at first visit (similar), distribution
of height (similar), distribution of menarchial age (simi-
lar), distribution (similar) and mean (both 28.5 days) of
the length of menstrual cycle, and distribution (similar)
and mean (5.1 and 5.0 days) of the duration of menstrual
period. Record linkage to the population register showed
that cases somewhat more often had children (not statis-
tically significant).
Most study women had used OCs while customers of the
HSHS or before that, and started the use at the age of 20
or later. The mean age was 22.6 years (SD = 3.2) among
cases and 22.3 (3.2) among controls. Starting young in-
creased by time: 3% of the women born between 1947
and 1950 (n= 220), 10% of those born between 1951 and
1955 (n = 138), and 24% of those born between 1956 and
1960 (n = 110) started before 20 years of age. Most wom-
en had started their OC use before first birth. 80% of OC
users had made last visit to HSHS when they were 25 years
or younger. The length of OC use as noted in the records
was 3 years or less among most women, with means 2.6
years (SD = 2.5) for cases and 2.9 (2.3) for controls.
Compared to those few women who had not used OC,
OC users had a higher risk of breast cancer (Table 2). Ad-
justment for confounders did not abolish the difference.
Among OC users, those who had started young did not
have a higher risk of breast cancer than those who had
started older (25 or more) (Table 3). There was also no
difference in the risk of breast cancer in regard to whether
the use was started before or after the first birth, or in re-
gard to having not given birth, Table 4. There was no dif-
ference in the risk of breast cancer among women who
had been pregnant while in the HSHS in regard to wheth-
er they had used OCs before or only after the first preg-
nancy.
When OC users were compared in terms of the time inter-
val from the first use to the first birth, no statistically sig-
nificant differences in the risk of breast cancer were found.
When users having the time interval 1 to 5 years were used
as the reference category, the adjusted odds ratio for the 6-
to 10- year interval was 0.7 (95 % CI 0.4, 1.3) and for the
11- to 20- year interval it was 0.8 (0.3, 1.9).
When we compared OC users by the age at start of OC use
and relation to first pregnancy, no statistically significant
differences were found. Women who started young (less
than 23 years) and before their first pregnancy did not
have a higher risk (OR 1.1, 95% CI 0.7, 1.8) than other
OC users.
Feasibility
University students were chosen as the study population
because we assumed them to be the first to adopt theBMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/9
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Table 1: Percentage distributions or means (standard deviation, SD) of cases with breast cancer and their controls by study character-
istics in the HSHS cohort
Study characteristic Percentage or mean
Cases n = 150 Controls n = 316
Year of birth, %
1946–1950 48 47
1951–1955 29 30
1956–1960 23 24
First visit at the HSHS, %
1965–1969 19 14
1970–1974 39 41
1975–1995 43 45
Smoking, %
Current 23 29
Quitted 3 6
Never 58 55
No information 16 10
Alcohol use, %
Moderate or heavy 17 18
Slight 37 38
No 9 15
No information 37 29
Sports, %
Active 21 35
No 53 44
No information 26 21
Weight (kg), mean (SD) 57.0 (7.1) 56.2 (7.6)
Height (cm), mean (SD) 166 (5.2) 165 (5.6)
Age at menarche (in years), mean (SD) 12.8 (1.2) 12.7 (1.2)
Contraception *, % 94 88
Any births ‡, % 73 67
Age at first delivery § (in years), %
18–24 17 20
25–29 48 49
30–34 29 26
35–41 5 5
Mean (SD) 28.1 (3.7) 27.7 (4.1)
*Any method recorded by the HSHS at any time. ‡ Births in Central Population Register before year of case's diagnosis. §Delivery before year of 
case's diagnosis.
Table 2: Odds ratios (OR) with 95% confidence intervals (CI) for breast cancer related to the use of oral contraceptives (OCs) while 
customer of the HSHS or before that.
OC user Cases Controls Crude Adjusted*
n% n % O R O R 9 5 %  C I
No † 15 10 57 18 1 1
Yes 114 76 222 70 2.1 2.1 (1.1, 4.2)
Not recorded 21 14 37 12 1.9 1.6 (0.6, 4.0)
Total 150 100 316 100
*Adjusted for parity and age at delivery (no births before year of case's diagnosis, birth before 25 years, other), sports (no sports, sports, unknown), 
and smoking (never, ever, unknown). † Reference group.BMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/9
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modern pattern of OC use: starting young and having
long use before first birth. Furthermore, many of them
had used only one service that has feasible archiving sys-
tem, as well as computerised registers with unique person-
al ID-numbers, making record linkage easy. We matched
the cases and controls by age and they all were university
students. Our assumption about there being many young
starters in this data set turned out to be wrong: only
among the youngest cohort, born in the latter half of the
1950s, was OC use before the age of 20 years common.
We also had very few non-users. OC use seems to have
spread among students very rapidly and almost everyone
at lest experimented with them.
Discussion
The hypothesis that OC use is related to breast cancer in
young age received limited support. But no clear relation
was found with starting age or starting before first birth.
We could not study the impact of the length of OC use be-
cause we had no data on the women's OC use after their
student years. A side finding was that cases were less likely
to have been active in sports, either competitive or recrea-
tional, at their first visit. This is in accordance with earlier
literature [30,31].
Several methodological problems, however, weaken these
findings. The main problems were, as described above,
small numbers of young starters, few non-users, and few
starters after first birth. Furthermore, because of our crite-
rion of at least 3 visits to HSHS, we very likely proportion-
ally selected out more non-users than users of OC: one of
the important reasons for HSHS visits was to get OC. Be-
cause more control (84%) than case women (63%) were
excluded because of this limit, we were likely to propor-
tionally exclude more non-users among the controls. Ac-
cordingly our analysis may underestimate the relation
between OC use and breast cancer. In hindsight, the draw-
backs of the potential bias caused by this criterion surpass
the benefits, and we should not have used such a criterion.
A strength of our study was that the data on exposure were
based on patient records. Because of the eligibility re-
quirement of at least three visits, it is likely that we have
relatively complete information on OC use while the
Table 3: Odds ratios (OR) with 95% confidence intervals (CI) for breast cancer related to age at start of oral contraceptive (OC) use‡.
Age at start of OC use (in years) Cases Controls Crude Adjusted*
n n OR OR 95% CI
16–19 11 36 0.6 0.5 (0.2, 1.6)
20–24 77 140 0.9 0.9 (0.5, 1.9)
≥  25† 21 40 1 1
Age missing 5 6 .. ..
‡ Women missing information about OC use or (21 cases and 37 controls) or not having used OCs while in the HSHS (15 cases and 57 controls) 
were excluded. *Adjusted for parity and age at delivery (no births before year of case's diagnosis, birth before 25 years, other), sports (no sports, 
sports, unknown), and smoking (never, ever, unknown). † Reference group.
Table 4: Odds ratios (OR) with 95% confidence intervals (CI) for breast cancer associated with use of oral contraceptives (OCs) in re-
lation to the first birth‡.
Use of OC Cases Controls Crude Adjusted*
n n OR OR 95% CI
User after 1st birth † 7 12 0.8 0.8 (0.2, 2.5)
User before 1st birth 74 143 1.1 1.0 (0.5, 1.7)
User, no births 32 62 1 1
Order of use and births** not known 1 5
‡ Women missing information about OC use or (21 cases and 37 controls) or having not used OCs while in the HSHS (15 cases and 57 controls) 
were excluded. *Adjusted for sports (no sports, sports, unknown) and smoking (never, ever, unknown). † Reference group. **Chronological order 
of the first delivery and start of OC use.BMC Women's Health 2002, 2 http://www.biomedcentral.com/1472-6874/2/9
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women were students in Helsinki. The information on
their status before they entered the HSHS was based on
women's interviews as noted in the patient records, and
may be incomplete. These inaccuracies in exposure data
weaken the comparisons between different user groups.
The comparison between cases and controls was made
with the assumption that the omissions were similar in
these two groups. We excluded women who had breast
cancer before their first HSHS visit, but women who had
it between the first and the third visit were included. Inclu-
sion of these women makes our finding of an increased
risk for breast cancer due to OC use conservative. On the
other hand, if the women classified as 'OC use not record-
ed' were in fact non-users, the association between OC use
and breast cancer becomes much smaller.
Most earlier case-control studies on OC use have relied on
women's (or their relatives') memory of OC use. Com-
pared to such an approach, our information on exposure
is more accurate in terms of starting age and relation to the
first birth (and type of drug, not analysed here). But we
could not adjust for current OC use, which has been
found to be a risk factor for breast cancer [1]. Nor do we
have data of the length of OC use.
Because adoption of the modern pattern of OC use was
not common among students, it is unlikely that the im-
pact of early and extended OC use can be studied before
2010, when women born in the 1960s are 40 to 50 years
old. Studies before that have to focus on either the impact
on very early breast cancer, which is rare and may be dif-
ferent (e.g. due to genetic predisposition) from breast can-
cer emerging around menopause, or focus on women
whose OC-use patterns are very different from those of
other women. Such women are likely to differ from others
on many dimensions and confounding by unknown fac-
tors may be large.
The case of OC use well illustrates the difficulty of evalu-
ating the long-term health impact of medical technolo-
gies. The true impacts may be revealed only after decades
of use, and often only after the technology is no longer in
use. In the case of OCs, the technology itself is still in wide
use, but the use patterns, user groups and chemical com-
position of the drugs have changed. The results of our
study concern a population of women who started OC use
before their first birth and pregnancy, who were much
older than the current OC-user population, and who used
OCs differing in composition and chemical strength from
those used today.
Conclusions
The hypothesis that OC use is related to breast cancer in
young age received only limited support. Our study wom-
en commonly used OC before first birth, but started their
use at a later age. The impact of young starting age in this
population can be studied only later, e.g. after a decade or
so.
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